查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984138

中轴型脊椎关节炎市场：依产品类别、治疗线、给药途径、通路及最终用户划分－2026-2032年全球预测

Axial Spondyloarthritis Market by Product Class, Treatment Line, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，中轴型脊椎关节炎市场价值将达到 7.2314 亿美元，到 2026 年将成长至 9.618 亿美元，到 2032 年将达到 54.0203 亿美元，复合年增长率为 33.27%。

主要市场统计数据
基准年 2025 7.2314亿美元
预计年份：2026年 9.618亿美元
预测年份 2032 54.203亿美元
复合年增长率 (%) 33.27%

对中轴型脊椎关节炎进行全面概述，重点关注临床复杂性、诊断障碍、治疗模式以及影响相关人员决策的不断变化的优先事项。

中轴型脊椎关节炎是一种复杂的慢性发炎性疾病，主要涉及脊椎和骶髂关节，导致许多患者出现疼痛、僵硬和长期功能障碍。由于症状多样、与机械性腰痛症状重迭，以及需要将临床评估与影像学和生物标记资讯结合，临床医生面临诊断上的挑战。儘管免疫学和分子医学的进步正在重塑我们对该疾病的临床认识，但在早期检测、治疗顺序和长期管理策略方面仍然存在挑战。

临床、医疗保健服务和基于价值的转型正在共同努力，重新定义整个护理路径中中轴型脊椎关节炎的诊断、治疗和管理。

中轴型脊椎关节炎的治疗格局正在经历一场变革，这主要得益于标靶治疗的突破性进展、不断更新的安全性证据以及患者期望的改变。白细胞介素-17抑制剂和Janus激酶抑制剂的出现，拓展了肿瘤坏死因子抑制剂以外的治疗选择，促使临床医师重新评估治疗顺序和个人化策略。同时，越来越多的真实世界数据和註册登记数据揭示了不同患者亚群间治疗反应的差异，从而推动了更精细的治疗流程的製定，并更加註重长期疾病控製而非暂时缓解症状。

为应对关税和全球贸易中断带来的成本压力，医疗保健服务正在受到衝击，供应链韧性、临床营运和合约策略正在重新评估。

贸易政策的转变，包括2025年生效的关税调整，为支撑中轴型脊椎关节炎生物製药和小分子化合物供应的全球供应链带来了新的复杂性。由于原料药和成品进口关税的提高，导致接收成本上升，并对现有定价协议构成压力，製药企业和经销商被迫重新评估筹资策略。儘管一些公司长期以来一直在分散其製造地，但关税的引入加速了关于近岸外包、双重采购和战略性库存布局的讨论，以维持治疗的连续性并最大限度地减少对关键患者群体的影响。

按产品类别、治疗线、分销管道、给药途径和最终用户进行详细细分，可以揭示临床和商业策略中可操作的差异化因素。

详细的細項分析揭示了产品类别、治疗线、分销管道、给药途径和终端用户环境等方面的显着趋势，所有这些因素都对临床和商业选择产生重大影响。在产品类别中，传统的缓解疾病抗风湿药物（DMARDs），包括羟氯喹、胺基甲基叶酸和柳氮磺吡啶，在特定患者群体中继续发挥至关重要的作用，尤其是在临床医生寻求控制合併症或限制生物製药暴露时。 IL-17抑制剂，例如Brodalumab 、ixekizumab和sectinimab，在轴性发炎生物标记和临床表型提示高反应机率的领域中，正在开闢独特的市场。 JanusJanus抑制剂，包括filgotinib、tofacitinib和Upadacitinib ，为寻求便捷和快速症状控制的患者提供了极具吸引力的口服标靶治疗。

区域间在监管、支付模式和医疗保健基础设施方面的差异正在扰乱医疗服务取得途径，因此需要根据当地情况制定证据和分发策略来应对这些挑战。

区域趋势反映了流行病学、法规环境、支付方框架和医疗服务基础设施的差异，这些差异影响着医疗服务的可近性和策略。在美洲，医疗保健系统由私人和公共支付机制混合组成，重点在于以结果为导向的合约和专科药房网络，这些都有助于患者获得先进的生物製药和口服标靶治疗。在该地区，真实世界数据（RWD）计划和患者登记系统正越来越多地被用于支持价值提案和报销谈判，而远端医疗的扩展则加强了远端监测和用药依从性支持。

竞争优势取决于差异化的证据、一体化的患者支持、可靠的供应以及贯穿整个治疗生命週期的策略伙伴关係。

中轴型脊椎关节炎领域的竞争格局由成熟的生物製药製剂产品线、新兴的定向小分子药物以及提供输注、配送和患者支持的专业服务供应商共同塑造。现有的肿瘤坏死因子抑制剂产品组合继续利用多年的临床经验和广泛的安全性数据集，而包括白细胞介素-17抑製剂和Janus激酶抑製剂在内的新型药物类别则致力于在特定患者群体中展现临床差异化疗效，并提供替代给药途径或更便捷的给药方式。

要将临床创新转化为对患者的永续影响，优先考虑综合证据产生、供应弹性、支付方合作、个人化商业化和教育至关重要。

产业领导者应优先考虑一系列切实可行且影响深远的倡议，以应对临床复杂性、政策变化和商业性压力。首先，他们应透过投资比较疗效研究、真实世界数据收集和患者报告结局研究，使证据生成与监管机构和支付方的期望保持一致，从而明确长期获益和安全性。其次，他们应透过製造地多元化、策略性库存管理和物流伙伴关係来增强供应链韧性，从而减轻贸易政策和关税带来的衝击。

我们以证据为基础的跨学科调查方法，结合同行评审的科学论文、专家访谈、监管分析和营运情报，产生可操作的临床和商业性见解。

这项综合分析是基于跨学科调查方法，整合了第一手和第二手资料、专家咨询以及结构化的证据评估，从而对中轴型脊椎关节炎进行了全面的观点。临床和科学文献、指南文件、监管资讯以及同行评审的研究构成了该疾病病理生理学、治疗机制和安全性特征的基础。此外，还透过对临床医生、专科药剂师和市场进入管理人员的专案访谈，补充了上述研究结果，以了解真实世界的临床实践模式、诊断流程以及与支付方的谈判趋势。

整合临床进步、营运韧性和策略伙伴关係，以建立一致的方法，加速以病人为中心的治疗效果和永续的医疗服务取得。

中轴型脊椎关节炎在临床创新和策略行动方面既带来了持续的挑战，也蕴藏着巨大的机会。儘管诊断延迟和患者间反应的差异性持续使治疗路径复杂化，但包括生物製药和标靶小分子药物在内的治疗选择不断扩展，为持续控制疾病和长期改善功能开闢了新的途径。政策趋势和贸易动态虽然增加了营运的复杂性，但同时也推动了对供应链韧性、生产多元化和透明合约等方面的有益投资。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按产品分类的中轴型脊椎关节炎市场

  • 传统DMARD
  • IL-17抑制剂
  • JAK抑制剂
  • NSAIDs
  • TNF抑制剂

第九章：依治疗线分類的中轴型脊椎关节炎市场

  • 第一选择
  • 第二选择
  • 第三选择

第十章：中轴型脊椎关节炎市场：依给药途径划分

  • 注射药物
  • 静脉注射
  • 口服

第十一章：中轴型脊椎关节炎市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：中轴型脊椎关节炎市场：依最终用户划分

  • 居家照护
  • 医院
  • 专科诊所

第十三章：中轴型脊椎关节炎市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：中轴型脊椎关节炎市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 中轴型脊椎关节炎市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国中轴型脊椎关节炎市场

第十七章：中国中轴型脊椎关节炎市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Acelyrin, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-5C6F41F5AF7D

The Axial Spondyloarthritis Market was valued at USD 723.14 million in 2025 and is projected to grow to USD 961.80 million in 2026, with a CAGR of 33.27%, reaching USD 5,402.03 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 723.14 million
Estimated Year [2026] USD 961.80 million
Forecast Year [2032] USD 5,402.03 million
CAGR (%) 33.27%

A comprehensive orientation to axial spondyloarthritis highlighting clinical complexity, diagnostic barriers, treatment paradigms, and the evolving priorities shaping stakeholder decision-making

Axial spondyloarthritis represents a complex chronic inflammatory condition that primarily affects the spine and sacroiliac joints, producing pain, stiffness, and long-term functional impairment for many patients. Clinicians face diagnostic challenges driven by heterogenous symptom presentation, overlaps with mechanical back pain, and the need to combine clinical assessment with imaging and biomarker information. Advances in immunology and molecular medicine are reshaping clinical understanding, yet gaps persist in early identification, therapeutic sequencing, and long-term management strategies.

Patients commonly navigate protracted pathways before receiving a definitive diagnosis, which influences both clinical outcomes and healthcare resource utilization. In parallel, therapeutic decision-making increasingly integrates targeted biologics and small molecules alongside conventional disease-modifying agents and symptomatic management with nonsteroidal anti-inflammatory drugs. The commercial and clinical landscape is evolving as new mechanisms of action demonstrate differential efficacy across patient phenotypes, safety profiles, and routes of administration. Stakeholders must therefore balance efficacy, tolerability, patient preference, and delivery models to optimize adherence and outcomes.

This introduction sets the stage for a detailed exploration of transformative shifts, policy influences, segmentation-driven opportunity areas, regional dynamics, competitive interplay, and actionable recommendations. The objective is to equip clinicians, payers, life sciences executives, and distribution leaders with a concise yet comprehensive orientation to the current state and near-term inflection points in axial spondyloarthritis management.

Transformative clinical, delivery, and value-based evolutions are converging to redefine how axial spondyloarthritis is diagnosed, treated, and managed across care pathways

The treatment landscape for axial spondyloarthritis has entered a period of transformative change driven by breakthroughs in targeted therapies, evolving safety evidence, and shifts in patient expectations. The emergence of interleukin-17 inhibitors and Janus kinase inhibitors has broadened therapeutic options beyond tumor necrosis factor inhibitors, prompting clinicians to rethink sequencing and personalization strategies. At the same time, growing real-world evidence and registry data have begun to delineate differential responses among patient subgroups, prompting more nuanced treatment algorithms and a stronger focus on long-term disease control rather than transient symptom relief.

Concurrently, care delivery models are adapting to patient preferences for convenience and continuity. The proliferation of oral targeted therapies and optimized infusion or injection delivery protocols has intensified competition across routes of administration, while digital health platforms are augmenting monitoring, adherence support, and remote consultations. Payer frameworks are responding to these clinical advances with increasingly outcome-oriented reimbursement models; value frameworks now place greater emphasis on sustained functional improvement, reduced flares, and avoidance of long-term disability.

Finally, innovation extends beyond pharmacology into diagnostics and biomarkers that aim to shorten diagnostic delay and enable precision prescribing. These diagnostic advances, paired with evolving clinical practice guidelines and multidisciplinary care pathways, are collectively reshaping how patients are identified, treated, and monitored, creating new windows for strategic investment and care model redesign.

Supply chain resilience, clinical operations, and contracting strategies are being reoriented in response to tariff-driven cost pressures and global trade disruptions affecting therapy access

Trade policy shifts, including tariff adjustments enacted in 2025, have injected new complexity into the global supply chains that underpin biologic and small molecule availability for axial spondyloarthritis. Pharmaceutical manufacturers and distributors have had to reassess sourcing strategies as increased duties on active pharmaceutical ingredients and finished product imports elevate landed costs and pressure established pricing contracts. While some firms have long maintained diversified manufacturing footprints, the tariffs have accelerated discussions around nearshoring, dual-sourcing, and strategic inventory positioning to preserve continuity of care and minimize disruption to critical therapeutic cohorts.

Clinical trial operations have also felt the ripple effects as sponsors re-evaluate site selection, import/export logistics for investigational products, and the cost calculus associated with multinational protocol execution. Regulatory authorities and ethical review boards have engaged with sponsors to ensure participant access is not compromised in cross-border studies, particularly where specialized biologic formulations require controlled temperature logistics and robust distribution partners. Health systems and payers are scrutinizing the downstream impact on formulary decisions and procurement cycles, weighing the cost pressure against clinical necessity and negotiated rebates or patient access programs.

In response, commercial teams are recalibrating contracting strategies with payers and distributors, emphasizing transparent cost drivers and supply continuity assurances. Manufacturers with integrated supply chain capabilities are better positioned to mitigate near-term volatility, while others are exploring collaborative frameworks with logistics partners to stabilize delivery timelines. Ultimately, tariff-induced pressures are catalyzing a strategic reorientation toward supply resilience, pricing transparency, and adaptive commercialization tactics that preserve patient access amid shifting trade environments.

Granular segmentation across product classes, treatment lines, channels, administration routes, and end users reveals actionable differentiation in clinical and commercial strategies

Deep segmentation analysis reveals differentiated dynamics across product classes, treatment lines, distribution channels, routes of administration, and end-user settings that materially influence clinical and commercial choices. Within product classes, conventional disease-modifying antirheumatic drugs encompass agents such as hydroxychloroquine, methotrexate, and sulfasalazine that remain foundational for certain patient profiles, particularly when clinicians aim to manage comorbid features or limit exposure to biologics. IL-17 inhibitors, represented by brodalumab, ixekizumab, and secukinumab, have carved a distinct niche where axial inflammation biomarkers and clinical phenotype suggest higher likelihood of response. Janus kinase inhibitors including filgotinib, tofacitinib, and upadacitinib provide an oral targeted option that appeals to patients seeking convenience and rapid onset of symptomatic control.

Nonsteroidal anti-inflammatory drugs such as diclofenac, ibuprofen, and naproxen continue to play a central role for symptomatic relief and flare management, while the broad class of tumor necrosis factor inhibitors, including adalimumab, certolizumab, etanercept, golimumab, and infliximab, remains a proven cornerstone for many moderate-to-severe cases. Treatment line segmentation further shapes clinical pathways: first-line approaches emphasize rapid inflammation control and functional preservation, second-line decisions reflect response durability and safety trade-offs, and third-line strategies integrate prior biologic exposure, comorbidity profiles, and tolerance history.

Distribution channel and route of administration considerations also inform adoption patterns. Hospital pharmacies and specialty clinics often manage infusion-based regimens and initial biologic initiations, whereas retail and online pharmacies facilitate maintenance dispensing, home administration, and adherence support for oral and injectable therapies. Injectable, intravenous, and oral routes each carry implications for patient convenience, monitoring requirements, and cost structures. End-user segmentation across home care, hospitals, and specialty clinics determines where education, infusion capacity, and long-term monitoring resources must be concentrated to ensure optimal outcomes. Taken together, these intersecting segmentation layers reveal clear opportunities for targeted clinical protocols, differentiated commercial approaches, and channel-specific patient support models.

Regional variations in regulation, payer models, and healthcare infrastructure create differentiated pathways to access that require customized evidence and distribution strategies

Regional dynamics reflect divergent epidemiology, regulatory environments, payer frameworks, and healthcare delivery infrastructures that shape access and strategy. In the Americas, health systems exhibit a mix of private and public payer mechanisms with an emphasis on outcomes-based contracting and specialty pharmacy networks that can facilitate access to advanced biologics and oral targeted agents. Real-world data initiatives and patient registries in this region are increasingly leveraged to support value narratives and reimbursement discussions, while telehealth expansion has strengthened remote monitoring and adherence interventions.

The Europe, Middle East & Africa region presents varied regulatory landscapes and procurement practices. In parts of Europe, centralized reimbursement deliberations and health technology assessment processes place significant weight on comparative effectiveness, quality-of-life outcomes, and long-term safety data. In the Middle East and Africa, variable infrastructure and funding models create pockets of both advanced specialty care delivery and constrained access, making partnerships with regional distributors and investment in local capacity building strategic priorities for manufacturers and service providers.

Asia-Pacific is characterized by rapid adoption of innovative therapies in certain markets, alongside distinct regulatory pathways and local manufacturing expectations in others. National strategies emphasizing domestic pharmaceutical capabilities and evolving reimbursement policies influence how novel agents are introduced and scaled. Cross-border supply chain considerations and differing clinical guideline adoption timelines further contribute to a mosaic of access and uptake patterns. Across all regions, stakeholders benefit from tailoring clinical evidence generation, market access strategies, and distribution partnerships to the specific regulatory, payer, and infrastructure realities they face.

Competitive advantage will depend on differentiated evidence, integrated patient support, supply reliability, and strategic partnerships across the therapy lifecycle

Competitive dynamics in axial spondyloarthritis are shaped by established biologic franchises, emergent targeted small molecules, and specialized service providers that support infusion, distribution, and patient support. Incumbent tumor necrosis factor inhibitor portfolios continue to leverage long-standing clinical experience and extensive safety datasets, while newer classes, including interleukin-17 inhibitors and Janus kinase inhibitors, concentrate on demonstrating clinical differentiation in specific patient cohorts and offering alternative routes of administration or dosing convenience.

Strategic imperatives for leading companies include deep investment in head-to-head and real-world comparative studies, development of robust patient support ecosystems to facilitate adherence for home-administered therapies, and expansion of manufacturing or distribution capabilities to ensure supply continuity. Partnerships between pharmaceutical sponsors and specialty pharmacy networks or infusion service providers are increasingly common as a means to streamline initiation, monitoring, and reimbursement workflows. Additionally, companies are prioritizing lifecycle management through formulation improvements, indication expansion studies, and evidence generation that supports positioning across treatment lines.

New entrants and smaller biopharma players are differentiating through niche clinical programs, biomarker-driven trials, and collaborations with diagnostic developers to enable more targeted prescribing. For commercial leaders, the ability to align clinical value messaging with payer expectations, demonstrate operational excellence in supply and distribution, and deploy digital-first patient engagement tools will determine competitive positioning and long-term success in the axial spondyloarthritis landscape.

Prioritize integrated evidence generation, supply resilience, payer collaboration, tailored commercialization, and education to convert clinical innovation into sustainable patient impact

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate clinical complexity, policy shifts, and commercial pressures. First, align evidence generation with both regulatory and payer expectations by investing in comparative effectiveness research, real-world data capture, and patient-reported outcome studies that clarify long-term benefits and safety profiles. Second, strengthen supply chain resilience through diversification of manufacturing footprints, strategic inventory management, and collaborative logistics partnerships that mitigate trade-policy and tariff-related disruptions.

Third, design tailored commercialization strategies that consider the interplay between product class, treatment line, distribution channel, and route of administration; for example, pairing oral targeted therapies with digital adherence programs and leveraging specialty pharmacy networks for complex biologic initiations. Fourth, engage proactively with payers and health technology assessment bodies to co-develop value propositions that emphasize functional outcomes, reduction in flares, and long-term disability avoidance rather than episodic symptom relief. Finally, invest in clinician and patient education to shorten diagnostic delays and support shared decision-making, thereby improving initiation timing and persistence with high-value therapies.

Taken together, these actions form an integrated roadmap that balances clinical innovation with operational readiness and market access acumen, enabling organizations to sustain growth while improving patient outcomes in axial spondyloarthritis.

A multidisciplinary, evidence-weighted methodology combining peer-reviewed science, expert interviews, regulatory analysis, and operational intelligence to produce actionable clinical and commercial insights

This research synthesis draws on a multidisciplinary methodology that integrates primary and secondary sources, expert consultations, and structured evidence appraisal to deliver a comprehensive perspective on axial spondyloarthritis. Clinical and scientific literature, guideline documents, regulatory communications, and peer-reviewed studies provided the foundation for disease biology, therapeutic mechanisms, and safety profiles. These insights were augmented by targeted interviews with clinicians, specialty pharmacists, and market access leads to capture real-world practice patterns, diagnostic workflows, and payer negotiation dynamics.

Supply chain and policy analyses incorporated trade publications, manufacturer disclosures, and logistics partner briefings to assess the operational impacts of tariff changes and distribution constraints. Competitive landscape mapping involved a synthesis of public company disclosures, clinical trial registries, and product labeling to evaluate positioning, development strategies, and lifecycle management approaches. Evidence quality was graded using transparent criteria that emphasized study design, population relevance, and applicability to contemporary clinical practice.

Where possible, synthesis favored longitudinal and comparative data to illuminate differential effectiveness and safety patterns. The methodological approach balanced depth with pragmatic relevance, aiming to produce findings that are both evidence-based and actionable for clinical leaders, commercial strategists, and policy stakeholders.

Synthesize clinical advances, operational resilience, and strategic partnerships into a cohesive approach that accelerates patient-centered outcomes and sustainable access

Axial spondyloarthritis presents both persistent challenges and clear areas of opportunity for clinical innovation and strategic action. Diagnostic delays and heterogenous patient responses continue to complicate care pathways, yet the expanding therapeutic arsenal-including biologics and targeted small molecules-offers new avenues to achieve durable disease control and improve long-term function. Policy developments and trade dynamics introduce operational complexity, but they also motivate beneficial investments in supply resilience, manufacturing diversification, and transparent contracting.

Strategically, successful stakeholders will align robust evidence generation with pragmatic commercialization and access tactics that reflect segment-specific drivers, regional regulatory realities, and evolving payer expectations. Partnerships across the ecosystem-from diagnostics and specialty pharmacies to distribution and digital health providers-can accelerate adoption and optimize patient journeys. Ultimately, the path forward requires coordinated efforts that combine clinical rigor, operational excellence, and a patient-centered focus to translate therapeutic advances into measurable improvements in quality of life for people living with axial spondyloarthritis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Axial Spondyloarthritis Market, by Product Class

  • 8.1. Conventional DMARDs
  • 8.2. IL-17 Inhibitors
  • 8.3. JAK Inhibitors
  • 8.4. NSAIDs
  • 8.5. TNF Inhibitors

9. Axial Spondyloarthritis Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Axial Spondyloarthritis Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Intravenous
  • 10.3. Oral

11. Axial Spondyloarthritis Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Axial Spondyloarthritis Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Axial Spondyloarthritis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Axial Spondyloarthritis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Axial Spondyloarthritis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Axial Spondyloarthritis Market

17. China Axial Spondyloarthritis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Acelyrin, Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca plc
  • 18.9. Biogen Inc.
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Eli Lilly and Company
  • 18.13. Gilead Sciences, Inc.
  • 18.14. Janssen Biotech, Inc.
  • 18.15. Kyowa Kirin Co., Ltd.
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Panacea Biotec Ltd.
  • 18.19. Pfizer Inc.
  • 18.20. Regeneron Pharmaceuticals, Inc.
  • 18.21. Sandoz International GmbH
  • 18.22. Sanofi S.A.
  • 18.23. Sun Pharmaceutical Industries Ltd.
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. Teva Pharmaceutical Industries Ltd.
  • 18.26. UCB S.A.
  • 18.27. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)